Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

This trial is testing whether giving an immunotherapy drug called atezolizumab (which helps the immune system attack cancer) in combination with other medications before surgical removal of the prostate can shrink or eliminate high-risk localized prostate cancer. **You may be eligible if...** - You have been diagnosed with prostate cancer confirmed by biopsy (adenocarcinoma) - You are eligible for and have agreed to a radical prostatectomy (complete surgical removal of the prostate) - You have high-risk prostate cancer (intermediate-risk patients may be included later after safety checks) - Tissue from your tumor is available for research analysis **You may NOT be eligible if...** - You have a rare subtype of prostate cancer (small cell or neuroendocrine) - Your surgeon has not confirmed you are eligible for surgery - Tumor tissue is not available for analysis - Your overall health is too poor to undergo surgery or the study treatments Talk to your doctor to see if this trial is right for you.